Indirect Costs Associated With Neovascular Age-Related Macular Degeneration (nAMD) in Colombia
Author(s)
Claudia A. López-Cabra, MSc, Médica epidemióloga1, Ángela Daniela Rodríguez, MSc, Economist2, Diana Smith Lopez, Esp., Economist2, Oscar A. Peñuela, MSc, Médico1, Juliana Nuñoz, Esp., Médica oftalmóloga1, Shirley Monsalve, Market Access1, wilson Mayorga Mogollon, MSc, Economist2;
1Bayer, Bogotá, Colombia, 2Numeris, Bogotá, Colombia
1Bayer, Bogotá, Colombia, 2Numeris, Bogotá, Colombia
Presentation Documents
OBJECTIVES: To calculate indirect costs associated with nAMD over a period of 2 years (2022 to 2023), based on data from survey 'A Global Survey of patients, providers, and clinic staff regarding the management of neovascular age-related macular degeneration (nAMD)' conducted globally, in which Colombia was a participating country
METHODS: Surveyed patients in Colombia were 283. Estimation was made in terms of productivity loss calculated from time spent on transportation and healthcare attention, including medical appointments, administration of Anti-VEGF therapies with/without caregiver, adjusted for the patient's age. Average transportation cost from cities where surveyed clinics are located was obtained, and average monthly salary of a worker/caregiver for 2022 from national survey “Gran Encuesta Integrada de Hogares (GEIH)” was calculated to estimate the foregone income of caregiver and patient, latter weighted by age and severe vision loss reported by the Global Burden of Disease (GBD) at 0.314. Results are reported for 2024, updated based on the Consumer Price Index (CPI)
RESULTS: Using an exchange rate of COP$4.061 Colombian pesos per US dollar (USD), total indirect costs for all surveyed patients and caregivers were USD$343.714 for analyzed years (USD$607 per patient/year). Transportation costs (including patients and caregivers) were estimated at USD$143.112 (USD$253 per patient/year). Most of surveyed patients had caregivers, some were relatives of patient (91,9%) and others regular paid caregiver/health worker (2,5%), so foregone income for relative caregivers’ time spent attending medical appointments at USD$60.011 (USD$249 per patient/year). Foregone income for the productivity losses for patients under 60 years old (11,3%) was USD$95.498 (USD$2.986 per patient/year)
CONCLUSIONS: Indirect cost of nAMD for patient/caregiver in a two-year period was USD$1,215. The increase in these indirect costs is related to the frequency of the treatment, highlighting the benefit that a treatment scheme such as the treat and extent could provide in terms of reduction of these costs
METHODS: Surveyed patients in Colombia were 283. Estimation was made in terms of productivity loss calculated from time spent on transportation and healthcare attention, including medical appointments, administration of Anti-VEGF therapies with/without caregiver, adjusted for the patient's age. Average transportation cost from cities where surveyed clinics are located was obtained, and average monthly salary of a worker/caregiver for 2022 from national survey “Gran Encuesta Integrada de Hogares (GEIH)” was calculated to estimate the foregone income of caregiver and patient, latter weighted by age and severe vision loss reported by the Global Burden of Disease (GBD) at 0.314. Results are reported for 2024, updated based on the Consumer Price Index (CPI)
RESULTS: Using an exchange rate of COP$4.061 Colombian pesos per US dollar (USD), total indirect costs for all surveyed patients and caregivers were USD$343.714 for analyzed years (USD$607 per patient/year). Transportation costs (including patients and caregivers) were estimated at USD$143.112 (USD$253 per patient/year). Most of surveyed patients had caregivers, some were relatives of patient (91,9%) and others regular paid caregiver/health worker (2,5%), so foregone income for relative caregivers’ time spent attending medical appointments at USD$60.011 (USD$249 per patient/year). Foregone income for the productivity losses for patients under 60 years old (11,3%) was USD$95.498 (USD$2.986 per patient/year)
CONCLUSIONS: Indirect cost of nAMD for patient/caregiver in a two-year period was USD$1,215. The increase in these indirect costs is related to the frequency of the treatment, highlighting the benefit that a treatment scheme such as the treat and extent could provide in terms of reduction of these costs
Conference/Value in Health Info
2025-05, ISPOR 2025, Montréal, Quebec, CA
Value in Health, Volume 28, Issue S1
Code
EE127
Topic
Economic Evaluation
Topic Subcategory
Work & Home Productivity - Indirect Costs
Disease
SDC: Sensory System Disorders (Ear, Eye, Dental, Skin)